dc.creator | Masson, Walter | |
dc.creator | Lobo, Martín | |
dc.creator | Siniawski, Daniel | |
dc.creator | Molinero, Graciela | |
dc.creator | Huerín, Melina | |
dc.creator | Nogueira, Juan Patricio | |
dc.date.accessioned | 2022-01-31T14:43:17Z | |
dc.date.accessioned | 2022-10-15T16:50:59Z | |
dc.date.available | 2022-01-31T14:43:17Z | |
dc.date.available | 2022-10-15T16:50:59Z | |
dc.date.created | 2022-01-31T14:43:17Z | |
dc.date.issued | 2019-08 | |
dc.identifier | Masson, Walter; Lobo, Martín; Siniawski, Daniel; Molinero, Graciela; Huerín, Melina; et al.; Impact of Lipid-Lowering Therapy on Mortality According to the Baseline Non-HDL Cholesterol Level: A Meta-Analysis; Springer; High Blood Pressure and Cardiovascular Prevention; 26; 4; 8-2019; 263-272 | |
dc.identifier | 1120-9879 | |
dc.identifier | http://hdl.handle.net/11336/150977 | |
dc.identifier | 1179-1985 | |
dc.identifier | CONICET Digital | |
dc.identifier | CONICET | |
dc.identifier.uri | https://repositorioslatinoamericanos.uchile.cl/handle/2250/4411583 | |
dc.description.abstract | Introduction: Previous report showed that more intensive lipid-lowering therapy was associated with less mortality when baseline LDL-C levels were > 100 mg/dL. Non-HDL-C is a better predictor of cardiovascular risk than simpler LDL-C. Aim: The objective of this meta-analysis was to define the impact of lipid-lowering therapy on the reduction of total and cardiovascular mortality by different baseline levels of non-HDL-C. Methods: We performed a meta-analysis including randomized, controlled clinical trials of lipid-lowering therapy, reporting mortality with a minimum of 6 months of follow-up, searching in PubMed/Medline, EMBASE and Cochrane Clinical Trials databases. The random-effects model and meta-regression were performed. Results: Twenty nine trials of lipid-lowering drugs, including 233,027 patients, were considered eligible for the analyses. According to the baseline non-HDL-C level, the results on cardiovascular mortality were: (1) ≥ 190 mg/dL: OR 0.63 (95% CI 0.53–0.76); (2) 160–189 mg/dL: OR 0.82 (95% CI 0.75–0.89); (3) 130–159 mg/dL: OR 0.71 (95% CI 0.52–0.98); (4) < 130 mg/dL: OR 0.95 (95% CI 0.87–1.05). When evaluating mortality from any cause, the results were the following: (1) ≥ 190 mg/dL: OR 0.70 (95% CI 0.61–0.82); (2) 160–189 mg/dL: OR 0.91 (95% CI 0.83–0.98); (3) 130–159 mg/dL; OR 0.88 (95% CI 0.77–1.00); (4) < 130 mg/dL: OR 0.98 (95% CI 0.91–1.06). The meta-regression analysis showed a significant association between baseline non-HDL-C and mortality.
Conclusions
In these meta-analyses, lipid-lowering therapy was associated with reduction in the risk of all-cause and cardiovascular mortality when baseline non-HDL-C levels were above than 130 mg/dL. | |
dc.language | eng | |
dc.publisher | Springer | |
dc.relation | info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1007/s40292-019-00330-8 | |
dc.rights | https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ | |
dc.rights | info:eu-repo/semantics/restrictedAccess | |
dc.subject | LIPID-LOWERING THERAPY | |
dc.subject | META-ANALYSIS | |
dc.subject | MORTALITY | |
dc.subject | NON-HDL-CHOLESTEROL | |
dc.title | Impact of Lipid-Lowering Therapy on Mortality According to the Baseline Non-HDL Cholesterol Level: A Meta-Analysis | |
dc.type | info:eu-repo/semantics/article | |
dc.type | info:ar-repo/semantics/artículo | |
dc.type | info:eu-repo/semantics/publishedVersion | |